{
    "clinical_study": {
        "@rank": "67123", 
        "arm_group": [
            {
                "arm_group_label": "Experimental group with 0-2-4-6 schedule", 
                "arm_group_type": "Experimental", 
                "description": "HB at 0, Eutravac at 2-4-6"
            }, 
            {
                "arm_group_label": "Active comparator group with 0-2-4-6 schedule", 
                "arm_group_type": "Active Comparator", 
                "description": "Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)"
            }, 
            {
                "arm_group_label": "Experimental group with 2-4-6 schedule", 
                "arm_group_type": "Experimental", 
                "description": "Eutravac at 2-4-6"
            }, 
            {
                "arm_group_label": "Active comparator group with 2-4-6 schedule", 
                "arm_group_type": "Active Comparator", 
                "description": "Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate and compare the immunogenicity of Eutravac (Diphtheria-Tetanus-acellular\n      Pertussis [DTaP] Hepatitis B [HB] combined) vaccine with separate but simultaneous\n      administrations of DTaP and HB vaccine each administered to healthy infants, as measured by\n      seroprotection/vaccine response rates 4-8 weeks post-final immunisation."
        }, 
        "brief_title": "A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Infants", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Were healthy, male or female infants born at full term pregnancy (\u226537 weeks) with a\n             birth weight \u22652.5 kg to mothers with a negative HBsAg serology, documented prior to\n             giving birth as per routine, site-specific ante-natal care procedures.\n\n          -  Signed parental or legally acceptable representative's informed consent was obtained\n\n        Exclusion Criteria:\n\n          -  Evidence of an acute febrile illness with axillary temperature \u226537.5\u2103 on the day of\n             the vaccination. Infants with symptoms of minor illness eg, mild gastroenteritis,\n             mild upper respiratory tract infection and who did not have a temperature \u226537.5\u2103 on\n             the day of the vaccination could be included at the Investigator's discretion\n\n          -  History of diphtheria, tetanus, pertussis or hepatitis B disease\n\n          -  History of any vaccine-related hypersensitivity or anaphylactic reaction after\n             previous administration of Euvax B"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "289", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896739", 
            "org_study_id": "LG-VACL004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Experimental group with 0-2-4-6 schedule", 
                "Active comparator group with 0-2-4-6 schedule", 
                "Experimental group with 2-4-6 schedule", 
                "Active comparator group with 2-4-6 schedule"
            ], 
            "intervention_name": "Eutravac", 
            "intervention_type": "Biological", 
            "other_name": [
                "LG DTaP Vaccine Inj. (DTaP)", 
                "Euvax B (Hepatitis B)", 
                "Hepavax (Hepatitis B)"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy infants with over than 37 weeks gestation periods.", 
            "over than 2.5Kg at at birth weight."
        ], 
        "lastchanged_date": "July 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "442-723"
                    }, 
                    "name": "The Catholic University of Korea ST. Vincent's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-723"
                    }, 
                    "name": "Daejeon St. Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "400-711"
                    }, 
                    "name": "Inha University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeju", 
                        "country": "Korea, Republic of", 
                        "zip": "690-767"
                    }, 
                    "name": "Jeju National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130-872"
                    }, 
                    "name": "Kyung Hee University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "139-709"
                    }, 
                    "name": "Korea Cancer Center Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-913"
                    }, 
                    "name": "Cha Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2,4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined Administered Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Seroprotection rate", 
            "safety_issue": "No", 
            "time_frame": "After final immunisation at 4-8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}